Fernando Anton-Moreno - Publications

Clinical Experience with Abemaciclib in Patients Previously Treated with Another CDK 4/6 Inhibitor in a Tertiary Hospital: A Case Series Study.

Journal: Cancers

Published: June 07, 2023

Correlation between breast cancer subtypes determined by immunohistochemistry and n-COUNTER PAM50 assay: a real-world study.

Journal: Breast cancer research and treatment

Published: January 25, 2023

Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2- advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial.

Journal: Breast (Edinburgh, Scotland)

Published: July 21, 2022

Case report: Clinical success targeting BRAF-mutated, hormone receptor positive, HER2- negative advanced breast cancer patient with BRAF-inhibitor plus MEK- inhibitor.

Journal: Frontiers in oncology

Published: July 18, 2022

Prospective, multicenter study on the economic and clinical impact of gene-expression assays in early-stage breast cancer from a single region: the PREGECAM registry experience.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: March 25, 2019

The economic burden of metastatic breast cancer in Spain.

Journal: European journal of hospital pharmacy : science and practice

Published: January 16, 2018

Safety of eribulin as third-line chemotherapy in HER2-negative, advanced breast cancer pre-treated with taxanes and anthracycline: OnSITE study.

Journal: The breast journal

Published: November 24, 2017

Critically short telomeres and toxicity of chemotherapy in early breast cancer.

Journal: Oncotarget

Published: October 25, 2016

18F-fluoromisonidazole PET and Activity of Neoadjuvant Nintedanib in Early HER2-Negative Breast Cancer: A Window-of-Opportunity Randomized Trial.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: March 28, 2016